<DOC>
	<DOCNO>NCT01716442</DOCNO>
	<brief_summary>Anti-CD20 agent propose rescue therapy refractory nephrotic syndrome ( NS ) basis favorable clinical observation . Yet long-term effect maintain remission likelihood become rituximab-dependent unclear information safety profile rituximab limit . This trial design investigate safety efficacy Rituximab child refractory NS .</brief_summary>
	<brief_title>Rituximab Trial Pediatric Nephrotic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>( A ) steroid/calcineurin inhibitor resistant nephrotic syndrome 1. steroid resistance : remission 4 week daily oral corticosteroid ( 60mg/m2/day ) 2. calcineurin inhibitor resistance : remission 3 month therapeutic dose administration cyclosporine and/or tacrolimus 3. remission define persistent proteinuria nephrotic range last 3 month 4. posttransplant patient include study ( B ) steroiddependent nephrotic syndrome 1 . Steroiddependent patient various know medication ( corticosteroid , cyclophosphamide , chlorambucil , calcineurin inhibitor , levamisole .. ) continuously 2 year 2. definition dependency : two consecutive relapse event 2 week discontinuation steroid calcineurin inhibitor improvement relapse frequency calcineurin inhibitor use unable continue calcineurin inhibitor due side effect unable continue calcineurin inhibitor due prolong use ( 2 year ) condition clinician considers difficult control disease steroid calcineurin inhibitor . previous rituximab use secondary nephrotic syndrome estimate GFR &lt; 60mL/min/1.73m2 50 % agematched standard GFR chronic acute active infection ( e.g . hepatitis B , C , herpes , varicella zoster ) prior live vaccine inoculation within 1 month ( study enrollment ) cardiovascular disease , pulmonary pleural disease uncontrolled hypertension leukocytopenia ( absolute neutrophil count &lt; 1500/mm3 ) thrombocytopenia ( &lt; 75000/mm3 ) pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>rituximab</keyword>
	<keyword>nephrotic</keyword>
	<keyword>refractory</keyword>
</DOC>